MetaCap

Evotec (EVO) vs Wave Life Sciences (WVE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evotec (EVO) has outperformed Wave Life Sciences (WVE) over the past year, losing 55.6% versus a loss of 63.7%. Over five years, WVE leads with a -35.8% price change compared with -94.4% for EVO. Wave Life Sciences is the larger company by market cap ($504.9 million vs $469.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVO-55.56%WVE-63.69%
+216%+69%-77%
Nov 21, 20251 yearNov 20, 2026
EVO-94.42%WVE-40.60%
+333%+109%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVO versus WVE key metrics
MetricEVOWVE
Share price$1.32$2.56
Market cap$469.11M$504.91M
1-day change-8.97%-5.88%
YTD return-57.14%-84.94%
1-year return-55.56%-63.69%
5-year return-94.44%-35.84%
EPS (TTM)$-0.59$-1.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$42.73M
Revenue growth (YoY)—-60.55%
Net income (latest FY)—$-204.38M
Operating margin—-504.09%
Net margin—-478.33%
52-week high$3.87$21.73
52-week low$1.32$2.55
Distance from 52-week high-65.89%-88.22%
Analyst consensusbuystrong_buy
Avg. price target upside+237.12%+549.61%
Average volume109.16K3.11M
Shares outstanding355.39M197.23M
Employees4,379317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

About Wave Life Sciences

WVE stock →

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

EVO vs WVE FAQ

Which is bigger, Evotec or Wave Life Sciences?

Wave Life Sciences (WVE) is larger, with a market capitalization of $504.91M compared with $469.11M for Evotec (EVO).

Which stock has performed better over the past year, EVO or WVE?

EVO returned -55.56% over the past 12 months, compared with -63.69% for WVE (price return, excluding dividends). Past performance does not predict future results.

Are Evotec and Wave Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons